


Targeting Key Aspects of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Tap NHL subtype to view enrolling trials.

Diseases listed reflect trial eligibility criteria on ClinicalTrials.gov and not necessarily those in which Bristol Myers Squibb is seeking a regulatory approval.^a

Progression From Naive B cell to Non-Hodgkin Lymphoma Subtypes of Interest¹



- Non-Hodgkin lymphomas are a clinically and genetically heterogeneous group of lymphoid malignancies⁶
- Chronic lymphocytic leukemia is a lymphoproliferative disease that includes lymph node involvement^{7,8}
- We are committed to applying our deep scientific understanding of disease biology and investigating agents targeting multiple pathways in NHL

ABC, activated B cell; BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; EBV+, Epstein-Barr virus positive; FL, follicular lymphoma; FL3B, follicular lymphoma Grade 3B; GCB, germinal center B cell; mAb, monoclonal antibody; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; PCNSL, primary central nervous system lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; T/HRBCL, T-cell/histiocyte-rich B-cell lymphoma; TFL, transformed follicular lymphoma; TMZL, transformed marginal zone lymphoma.
^aTrials listed here may include malignancies other than the NHL subtypes of interest shown.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

[References](#)